- Harmonizing Weight of Evidence Assessments: The PRAGMATIC Framework for Global Chemical Safety Evaluation
-
Hemisfair Ballroom C3‚ Convention Center
Chair: Amber Goetz, Syngenta Crop Protection LLC
Co-Chair: Victoria Yell, CropLife America
Primary Endorser: Regulatory and Safety Evaluation Specialty Section
Endorser(s): Women in Toxicology Special Interest GroupWeight of Evidence (WoE) assessments are fundamental to chemical safety evaluation, yet their implementation remains inconsistent across regulatory jurisdictions. Some agencies employ explicit, formalized frameworks with defined evaluation criteria, while others apply WoE principles implicitly, and still others do not formally recognize WoE assessments as satisfying regulatory data requirements. This variability creates significant challenges: divergent evaluations of the same substance across regions, reduced transparency in decision-making, inefficient use of scientific resources, and barriers to capacity-building in emerging regulatory systems. The absence of harmonized, operationally practical guidance on how to conduct WoE assessments has limited their consistent and transparent application globally. Critical gaps remain regarding when and how WoE should be utilized throughout the assessment lifecycle; transparent criteria for evaluating evidence relevance, reliability, and adequacy; reproducible approaches for weighting and integrating diverse data types, including traditional studies, mechanistic data, epidemiology, and New Approach Methodologies (NAMs); and best practices for communicating conclusions and characterizing uncertainty. This session introduces the PRAGMATIC (Practical Guidance for Implementing Weight-of-Evidence Assessments) as a harmonizing, “meta-framework” built upon OECD Guiding Principles and established regulatory practice. PRAGMATIC advances beyond existing approaches by defining a minimum, auditable set of WoE elements and providing operational guidance, including templates, evidence-appraisal criteria, integration-logic options, and uncertainty documentation, that can be mapped onto existing regional WoE processes rather than replacing them. A central focus is enabling consistent, fit-for-purpose incorporation of NAMs including in vitro, in silico, and high-throughput data alongside traditional studies and human evidence. Participants will learn how PRAGMATIC can be implemented across decision contexts, including hazard identification, potency/POD derivation, endocrine activity, and data waiver/testing strategies. This session will include regulatory perspectives a practical case study demonstrating how NAMs and traditional evidence can be integrated into a coherent, reviewable safety narrative. It will also critically examine the limitations, practical challenges, and potential critiques of harmonization approaches, including the need to accommodate jurisdiction-specific legal mandates, data requirements, decision contexts, and scientific conventions. Discussion will address how a harmonizing framework can promote transparency, consistency, and convergence without imposing inappropriate uniformity or diminishing regulatory flexibility.
Session and Activity Type
Enter Note
Go to previous page in this tab
Event
